C-Phycocyanin as a Precision Therapeutic Modulator of Epoxide Hydrolase Variants in Type 2 Diabetes and Cardiovascular Disease
Surya Pratap Singh* and Arbab Husain
Type 2 diabetes mellitus and cardiovascular diseases represent major global health challenges, often associated with metabolic dysregulation and enzyme mediated inflammatory pathways. Epoxide hydrolase enzymes play a critical role in lipid metabolism and vascular homeostasis, making them promising therapeutic targets. The present study investigates the potential of C-phycocyanin, a bioactive compound derived from cyanobacteria, as a modulatory agent against epoxide hydrolase variants implicated in these diseases.
A combination of computational and analytical approaches was employed to evaluate the interaction between C-phycocyanin and selected epoxide hydrolase protein structures. Molecular docking and binding affinity analyses were performed to assess the stability and specificity of ligand–protein interactions. Structural and functional insights were further analyzed using bioinformatics tools and statistical methods.
The results demonstrated significant binding affinity of C-phycocyanin toward key active sites of epoxide hydrolase, suggesting its potential inhibitory or modulatory role. Comparative analysis indicated favourable interaction energies and stable conformational binding, supporting its therapeutic relevance. These findings align with previous studies highlighting the anti-inflammatory and antioxidant properties of C-phycocyanin.
In conclusion, C-phycocyanin exhibits promising potential as a precision therapeutic modulator of epoxide hydrolase variants in metabolic and cardiovascular disorders. Further experimental validation and clinical studies are recommended to confirm its efficacy and translational applicability.
